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Summary
Design: A six-centre study in Japan during the winter of 1999—2000 assessed the in
vitro activity of >20 antimicrobial agents against the common respiratory pathogens
Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and
Moraxella catarrhalis. The minimum inhibitory concentrations (MIC) of each anti-
microbial was determined against these isolates using National Committee for Clinical
Laboratory Standards (NCCLS) methodology.
Results: Among S. pneumoniae isolates, 44.5% were penicillin resistant. The macro-
lide resistance rate was 77.9% with 90.5% of penicillin-resistant strains also being
macrolide resistant. Resistance mechanisms in macrolide-resistant isolates were
identified as mef(A) or erm(B) in 42.5% and 52.5%, respectively. Of the fluoroquino-
lone-resistant isolates (1.3%), most were also penicillin and macrolide resistant. All
strains were inhibited by telithromycin at 1 mg/L. Among S. pyogenes isolates,
erythromycin resistance was 17.5% overall but showed considerable variation among
the six centres. For H. influenzae, 8.5% produced b-lactamase and a single b-
lactamase-negative, ampicillin-resistant isolate (0.36%) was obtained, and there
was no fluoroquinolone resistance. All isolates were susceptible to telithromycin.
* Corresponding author. Tel.: +81 42 778 9355; fax: +81 42 778 9350.
E-mail address: matsu@kitasato-u.ac.jp (M. Inoue).
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rost antimicrobials showed good activity againstM. catarrhalis, although 96.7% were
-lactamase positive.
onclusion: The prevalence of antimicrobial resistance to macrolides, penicillin and
he fluoroquinolones among the common respiratory pathogens is high in Japan.
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The prevalence of resistant isolates of common
bacterial respiratory tract pathogens is increasing,
and nowhere more so than in Asia. In some Asian
countries, penicillin resistance may be as high as
70%.1—3 In the last decade, macrolide resistance has
also increased dramatically, exceeding penicillin
resistance in some areas,2 and growing resistance
to chloramphenicol, co-trimoxazole and tetracy-
cline continues relentlessly.4
Most respiratory tract infections are viral in origin
but are frequently followed by secondary infections
resulting from opportunistic invasion by commensal
respiratory bacteria. The four most important bac-
terial pathogens associated with community-
acquired upper and lower respiratory tract infec-
tions (RTIs — acute/chronic sinusitis, acute/chronic
otitis media, acute/chronic pharyngitis, commu-
nity-acquired pneumonia, acute bacterial exacer-
bation of chronic bronchitis and acute bacterial
exacerbation of chronic obstructive airways dis-
ease) are Streptococcus pneumoniae, Streptococcus
pyogenes, Haemophilus influenzae, and Moraxella
catarrhalis. Less commonly, atypical and intracel-
lular pathogens including Legionella pneumophila,
Mycoplasma pneumoniae, and Chlamydophila
(Chlamydia) pneumoniae are also found as causes
of community-acquired RTIs.5—7
S. pneumoniae in particular has acquired resis-
tance to several classes of antimicrobial com-
pounds, including penicillins, macrolides and
fluoroquinolones, by a variety of mechanisms.8
For Haemophilus species and M. catarrhalis, b-lac-
tamase production is the principal mechanism of
resistance to penicillins and cephalosporins. The
choice of antimicrobial therapy in community-
acquired RTIs is generally empirical and compli-
cated by increasing bacterial resistance. Effective
strategies for ensuring adequate antimicrobial ther-
apy are therefore necessary but may only be
achieved through an understanding of the geo-
graphic variation in resistance and by monitoring
trends in resistance development.
Established in 1999, PROTEKT (Prospective
Resistant Organism Tracking and Epidemiology for
the Ketolide Telithromycin) is an international
surveillance study to chart the prevalence ofimportant resistance phenotypes and examine the
susceptibility of community-acquired RTI pathogens
to a range of antimicrobial compounds. Telithromy-
cin is the first ketolide antibacterial to be approved
for clinical use for the treatment of upper and lower
RTIs. With over 35 countries and 500 centres now
participating, PROTEKT is able to concentrate on
defining trends in specific regions and countries.
Detailed data from the examination of isolates
of S. pneumoniae, H. influenzae, M. catarrhalis
and S. pyogenes collected during the 1999—2000
winter season in Japan are now presented and,
where possible, related to trends seen in previous
studies.2,9,10Materials and methods
Participating centres
During the 1999—2000 winter season, six centres
took part in the study: Kanagawa, Sendai, Tokyo
(two centres), Nagasaki and Osaka.
Bacterial isolates
Centres were asked to collect the following isolates
from patients with community-acquired upper and
lower RTIs: 40 isolates each of S. pneumoniae
and H. influenzae, 25 of S. pyogenes, and 20
of M. catarrhalis. Sources for isolates were cultures
from blood, sputum, bronchoalveolar lavage, mid-
dle ear fluid, nasopharyngeal swab or aspirate, and
sinus aspirate. Duplicate strains or strains originat-
ing from previous collections were not accepted.
Identification and antimicrobial
susceptibility testing
Isolates were identified at source and re-identified
at the central laboratory by methods previously
described in detail.11 Minimum inhibitory concen-
trations (MICs) were determined using previously
described broth microdilution methods,11 according
to the National Committee for Clinical Laboratory
Standards (NCCLS) of the USA guidelines, for the
following antimicrobial agents: amoxicillin—clavu-
lanate, cefaclor, cefcapene, cefdinir, cefditoren,
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erythromycin, roxithromycin, clarithromycin, azi-
thromycin, rokitamycin, minocycline, tetracycline,
ciprofloxacin, levofloxacin, sparfloxacin and tosu-
floxacin. MICs were also determined for penicillin
and clindamycin against S. pneumoniae and S. pyo-
genes isolates and for ampicillin and amoxicillin
against H. influenzae and M. catarrhalis isolates.
Test results were acceptable only if the MICs for
the control strains were within performance range.
The following control strains were used: S. aureus
ATCC 29213, E. coli ATCC 25922 and ATCC 35218,
H. influenzae ATCC 49766, H. influenzae ATCC
49247, and S. pneumoniae ATCC 49619.
Breakpoint concentrations used to interpret MIC
data qualitatively were based upon those published
by the NCCLS of the USA,12 where available. For
telithromycin, NCCLS approved (SAST 2003) break-
points were applied: S. pneumoniae: susceptible
1 mg/L, intermediate 2 mg/L, resistant 4 mg/
L; and for H. influenzae: susceptible 4 mg/L,
intermediate 8 mg/L, resistant 16 mg/L. No
NCCLS breakpoints are available for S. pyogenes
or M. catarrhalis.
b-lactamase detection
b-lactamase activity was detected using the chro-
mogenic cephalosporin (nitrocefin) test (Unipath
Ltd. Basingstoke, UK).
Macrolide resistance mechanism detection
For S. pneumoniae, the presence of resistance
mechanisms for both MLSB (erm) and M-resistance
(mef) was analysed using a rapid-cycle multiplex
PCR method with probe detection. This method
detects erm(A), erm(A) subclass erm(TR), erm(B),
erm(C), and mef(A) genes.13Table 1 Penicillin and macrolide susceptibility and cross
Japan.
Centre No. of isolates Pen-Ia P
n % n
Kanagawa 52 4 7.7
Sendai 38 12 31.6
Tokyo 1 54 11 20.4
Tokyo 2 62 10 16.1
Nagasaki 58 14 24.1
Osaka 44 10 22.7
Total 308 61 19.8 1
a Penicillin-intermediate: MIC 0.12—1 mg/L.
b Penicillin-resistant: MIC  2 mg/L.
c Erythromycin-resistant: MIC  1 mg/L.Results
Streptococcus pneumoniae
A total of 308 S. pneumoniae isolates from the six
participating centres were tested. The prevalence
of penicillin resistance (MIC 2 mg/L) was 44.5%
overall and ranged narrowly between 44.2% and
48.4% for five of the six centres, with Osaka lower
at 36.4%. Penicillin-intermediate (MIC 0.12—1 mg/
L) isolates (19.8% overall) were less evenly distrib-
uted, with centres reporting between 7.7% (Kana-
gawa) and 31.6% (Sendai) (Table 1). The prevalence
of macrolide resistance (erythromycin MIC 1 mg/
L) was 77.9%, far exceeding that of penicillin resis-
tance, and ranged from 67.3% (Kanagawa) to 86.4%
(Osaka) (Table 1). Only one strain was of the inter-
mediate type (erythromycin MIC 0.5 mg/L). Almost
half of all S. pneumoniae isolates (40.3%) were co-
resistant to penicillin and erythromycin (macrolide)
(Table 1).
Of the 239 macrolide-resistant isolates of S.
pneumoniae analysed for their resistance mechan-
ism, 52.7% carried erm(B) (MLSB resistance) and
42.7% carried mef(A) (efflux resistance), with
3.3% (n = 8) of isolates carrying both mechanisms
(mef(A)+erm(B)) (Table 2). ermB isolates were
evenly distributed across the three penicillin resis-
tance phenotypes, whereas mef(A) resistance was
associated predominantly with penicillin-resistant
(70.6%) rather than penicillin-susceptible (16.7%)
isolates.
Among the b-lactams, the most active were cef-
ditoren (MIC90 1 mg/L, 98.4% of all isolates suscep-
tible) and amoxicillin—clavulanate (MIC90 2 mg/L,
96.4% of all isolates susceptible). Both retained
>90% activity among the penicillin- and macro--resistance of Streptococcus pneumoniae isolates from
en-Rb Mac-Rc Pen-R/Mac-R
% n % n %
23 44.2 35 67.3 18 34.6
18 47.4 32 84.2 18 47.4
24 44.4 43 79.6 22 40.7
30 48.4 48 77.4 27 43.5
26 44.8 44 75.9 23 39.7
16 36.4 38 86.4 16 36.4
37 44.5 240 77.9 124 40.3
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Table 2 Effect of specific macrolide-resistance mutations for 239 macrolide-resistant isolates of Streptococcus
pneumoniae from Japan and classified by penicillin susceptibility phenotype.
Genotype MAC-Ra MIC range (mg/L) PEN-Sb PEN-Ic PEN-Rd
n % n % n % n %
mef(a) 102 42.7 1—128 17 16.7 13 12.7 72 70.6
erm(b) 126 52.7 32—128 44 34.9 34 27.0 48 38.1
mef(a) + erm(b) 8 3.3 64—128 2 25 2 25 4 50
None specified 3 1.3 64—128 3 100 0 0 0 0
a Macrolide-resistant (erythromycin MIC 1 mg/L).
b Penicillin-susceptible: MIC  0.06 mg/L.
c Penicillin-intermediate: MIC 0.12—1 mg/L.lide-resistant isolates (Table 3). With the exception
of telithromycin and the fluoroquinolones, suscept-
ibility to non-b-lactams was low (Table 3). Among
the penicillin-resistant isolates, <10% were suscep-
tible to macrolides and tetracycline.Table 3 Comparative in vitro activity and percentage sus
intermediate, penicillin-resistant and erythromycin-resistan
NCCLS (2002) interpretative breakpoints.
Antimicrobial All isolates (n = 308) PEN-Ia (n = 61)
MIC50
(mg/L)
MIC90
(mg/L)
%Sd MIC50
(mg/L)
MIC90
(mg/L)
Penicillin 0.5 4 35.7 0.25 1
Amoxicillin—
clavulanatee
0.5 2 96.4 0.25 0.5
Cefaclor 16 >64 20.8 16 64
Cefcapene 2 4 NA 2 4
Cefdinir 4 8 44.5 2 4
Cefditoren 0.5 1 98.4 0.5 1
Cefixime 16 32 —f 16 64
Cefpodoxime 2 4 40.3 2 4
Cefuroxime 4 8 41.2 4 8
Telithromycin 0.06 0.25 100g 0.06 0.5
Erythromycin 8 >64 21.8 64 >64
Roxithromycin 8 >32 NA >32 >32
Clarithromycin 4 >32 22.1 32 >32
Azithromycin 8 >64 21.8 64 >64
Rokitamycin 0.12 >32 NA 1 >32
Clindamycin 0.12 >4 54.9 4 >4
Minocycline 8 16 NA 16 16
Tetracycline >16 >16 20.8 16 >16
Ciprofloxacin 1 2 NA 1 2
Levofloxacin 1 1 96.4 0.5 1
Sparfloxacin 0.25 0.5 96.1 0.25 0.25
Tosufloxacin 0.12 0.12 NA 0.06 0.12
a Penicillin-intermediate: MIC 0.12—1 mg/L.
b Penicillin-resistant: MIC 2 mg/L.
c Erythromycin-resistant: MIC 1 mg/L.
d % of isolates susceptible.
e Also applies to amoxicillin.
f Susceptibility predicted from penicillin.
g NCCLS (SAST Jan 2003) approved breakpoint for telithromycin:Erythromycin, roxithromycin, azithromycin
and clarithromycin gave typical trimodal MIC dis-
tributions with clusters of isolates inhibited by
0.06—0.12 mg/L, 2—4 mg/L and >32—>64 mg/L
(Figure 1). Small numbers of isolates were inhibitedceptibility of various antimicrobials against penicillin-
t isolates of Streptococcus pneumoniae from Japan using
PEN-Rb (n = 137) MAC-Rc (n = 240)
%Sd MIC50
(mg/L)
MIC90
(mg/L)
%Sd MIC50
(mg/L)
MIC90
(mg/L)
%Sd
0 2 4 0 2 4 27.9
100 2 2 92.0 0.5 2 95.8
8.2 64 >64 0 2 4 11.3
NA 4 4 NA 2 4 NA
41.0 8 8 2.2 4 8 35.8
96.7 1 1 97.8 0.5 1 97.9
—f 32 64 —f 32 64 —f
36.1 2 4 0 2 4 32.1
37.7 8 8 0 4 8 33.3
100g 0.06 0.12 100g 0.06 0.25 100g
19.7 4 >64 9.5 64 >64 0
NA 8 >32 NA 64 64 NA
19.7 4 >32 9.5 32 >32 0
18.0 8 >64 9.5 64 >64 0
NA 0.12 >32 NA 1 64 NA
41.0 0.12 >4 62.0 4 >4 42.1
NA 8 16 NA 16 16 NA
18.0 >16 >16 9.5 >16 >16 4.2
NA 1 2 NA 1 2 NA
100 1 1 97.1 1 1 96.3
100 0.25 0.25 96.4 0.25 0.5 95.8
NA 0.06 0.12 NA 0.12 0.12 NA
susceptible 1 mg/L; NA = NCCLS breakpoints not available.
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Figure 1 MIC distribution for macrolide-lincosamide-streptogramin (MLS) class antimicrobials against Streptococcus
pneumoniae from Japan.by each inter-mode concentration of each antimi-
crobial. Rokitamycin and clindamycin showed two
obvious clusters in their MIC distributions, with just
under half the isolates inhibited within the lowest
concentration cluster. This was reflected in the
MIC50 (0.12 mg/L) for rokitamycin and clindamycin,
which differed considerably from the four macro-
lides with typical trimodal MIC distributions (MIC50
4—8 mg/L).
Telithromycin showed much lower mode MIC
(0.06 mg/L) and MIC90 (0.25 mg/L) than the macro-
lides (Figure 1). Among the macrolide-resistant iso-
lates, the telithromycin MIC90 value was markedly
higher for the erm(B) genotype (0.5 mg/L) than the
mef(A) genotype (0.12 mg/L). Despite a shift
upwards in the distribution of telithromycin MIC
values among the macrolide-resistant isolates (par-
ticularly among the eight erm(B)+mef(A) strains
(Figure 2)) compared with macrolide-susceptible
isolates (telithromycin MIC90 0.015 mg/L), all iso-
lates were susceptible to telithromycin at1 mg/L.
Fluoroquinolone resistance (levofloxacin MIC
8 mg/L) was 1.3% overall, with little variation
among centres. Of the four fluoroquinolone-resis-
tant isolates, three were penicillin-resistant and
one was penicillin-susceptible. All four fluoroquino-
lone-resistant isolates were also macrolide- and
tetracycline-resistant. Susceptibility to telithromy-
cin was unaffected by fluoroquinolone resistance.
Overall, of those antibacterial agents tested, the
most active against S. pneumoniae in the winterseason 1999—2000 in Japan (in terms of potency and
susceptibility percentage) were telithromycin,
sparfloxacin, levofloxacin, cefditoren and amoxicil-
lin—clavulanate.
Streptococcus pyogenes
The most potent antimicrobial against S. pyogenes
isolates was penicillin (MIC90 0.008 mg/L) against
which all 120 isolates were susceptible. Macrolide
resistance showed considerable variation among the
six centres, with the highest prevalence (42.1%) in
Sendai and 0% in Nagasaki (although this centre
collected only three isolates). Overall, 82.5% of
isolates were erythromycin-susceptible. Among
the 21 (17.5%) erythromycin-resistant isolates, the
mechanisms of resistance detected were mef(A) in
15 isolates, erm(A) subclass erm(TR) in five isolates
and erm(B) in one isolate. Telithromycin had mode
MIC (0.015 mg/L) and MIC90 (0.25 mg/L), values
which were 16- to 32-fold lower than those of the
tested macrolides.
Haemophilus influenzae
b-lactamase production amongst H. influenzae iso-
lates (n = 281) had an overall incidence of 8.5% and
variation among centres of 5.1% to 11.5%. A single
b-lactamase-negative, ampicillin-resistant (MIC
4 mg/L) strain (BLNAR) was identified (from Sen-
dai). A further nine b-lactamase-negative isolates,
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Figure 2 Telithromycin MIC distribution for macrolide-resistant genotypes of Streptococcus pneumoniae from Japan.however, had ampicillin MICs of 2 mg/L (intermedi-
ate resistance according to NCCLS breakpoints).
Comparative in vitro activity of all antimicrobial
compounds tested against H. influenzae and cate-
gorised by b-lactamase production is shown in Table
4. Of the b-lactams tested, cefditoren (MIC90
0.06 mg/L; no NCCLS breakpoint) and cefixime
(MIC90 0.25 mg/L; 100%) were the most active.
Chloramphenicol resistance had low prevalence
(3.6%), with nine of the ten nonsusceptible isolates
also b-lactamase-positive. Similarly, tetracycline
resistance was low (6.4%) with resistant isolates
predominantly b-lactamase-positive (12/18). The
MIC90 values for both chloramphenicol and tetracy-
cline among b-lactamase-positive H. influenzae iso-
lates (16 mg/L) were 16 times greater than for b-
lactamase-negative isolates (Table 4).
The MICs of the macrolides and telithromycin to
H. influenzae isolates followed unimodal distribu-
tions in the rank order: azithromycin (MIC90 1 mg/L)
> telithromycin (MIC90 2 mg/L) > rokitamycin
(MIC90 8 mg/L) > clarithromycin and roxithromycin
(MIC90 16 mg/L), (Table 4). There was no correlation
between ketolide/macrolide susceptibility and
b-lactamase production.Moraxella catarrhalis
Of the 122 M. catarrhalis isolates, 118 (96.7%) were
b-lactamase-positive. With the exception of some
b-lactams (ampicillin, cefaclor, cefuroxime and cef-
capene), all antimicrobials tested showed good
activity (MIC90 values of 1 mg/L) against M. catar-
rhalis isolates (Table 4). Cefixime was the most
active b-lactam (MIC90 0.25 mg/L), followed by
cefdinir and cefditoren (both, MIC90 0.5 mg/L)
(Table 4). The rank order of activity of the MLS class
of antimicrobials was azithromycin (MIC90 0.06 mg/
L)> telithromycin, clarithromycin, and rokitamycin
(MIC90 0.25 mg/L) > roxithromycin (MIC90 0.5 mg/
L). Sparfloxacin and tosufloxacin were the most
potent (MIC90 0.008 mg/L) fluoroquinolones.Discussion
Streptococcus pneumoniae
Previous reports have demonstrated the increasing
prevalence of penicillin resistance of both inter-
mediate (MIC 0.12—1 mg/L) and resistant (MIC
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Table 4 Comparative in vitro activity of various antimicrobials against isolates of Haemophilus influenzae and
Moraxella catarrhalis from Japan.
Antimicrobial Haemophilus influenzae Moraxella
catarrhalisa
All isolates
(n = 281)
b-lactamase
positive (n = 24)
b-lactamase
negative (n = 257)
All isolates
(n = 122)
MIC50
(mg/L)
MIC90
(mg/L)
%Sb MIC50
(mg/L)
MIC90
(mg/L)
%Sb MIC50
(mg/L)
MIC90
(mg/L)
%Sb MIC50
(mg/L)
MIC90
(mg/L)
Ampicillin 0.25 2 87.9 >16 >16 0 0.25 1 96.1 8 16
Amoxicillin—
clavulanate
0.5 2 99.3 1 2 100 0.5 2 99.2 0.12 0.25
Cefaclor 4 16 86.5 16 32 45.8 4 8 90.3 2 16
Cefcapene 0.5 1 NA 1 16 NA 0.5 4 NA 8 16
Cefdinir 0.25 1 91.8 0.5 2 79.2 0.25 1 93.0 0.12 0.5
Cefditoren 0.015 0.06 NA 0.015 0.12 NA 0.015 0.03 NA 0.12 0.5
Cefixime 0.03 0.25 100 0.12 0.5 100 0.03 0.25 100 0.25 0.25
Cefpodoxime 0.06 0.5 99.3 0.12 1 100 0.06 0.5 99.2 0.5 1
Cefuroxime 1 4 95.4 2 4 95.8 1 4 95.3 2 4
Telithromycin 1 2 100c 1 2 100c 1 2 100c 0.06 0.25
Roxithromycin 8 16 NA 8 8 NA 8 16 NA 0.25 0.5
Clarithromycin 8 16 88.3 8 16 75.0 8 16 89.5 0.25 0.25
Azithromycin 1 1 100 1 2 100 1 1 100 0.06 0.06
Rokitamycin 4 8 NA 4 8 NA 4 8 NA 0.25 0.25
Minocycline 1 2 NA 1 2 NA 1 2 NA 0.06 0.06
Tetracycline 0.5 1 93.6 1 16 50.0 0.5 1 97.7 0.25 0.5
Co-trimoxazole 0.06 0.06 97.9 0.06 4 87.5 0.06 0.06 98.8 0.12 0.25
Chloramphenicol 0.5 1.0 96.4 0.5 8 62.5 0.5 0.5 99.6 0.5 0.5
Ciprofloxacin 0.015 0.015 100 0.015 0.03 100 0.015 0.015 100 0.03 0.03
Levofloxacin 0.015 0.015 100 0.015 0.03 100 0.015 0.015 100 0.03 0.03
Sparfloxacin 0.004 0.008 99.3 0.008 0.008 100 0.004 0.008 99.2 0.008 0.008
Tosufloxacin 0.004 0.008 NA 0.008 0.008 NA 0.004 0.008 NA 0.008 0.008
a NCCLS breakpoints not available for M. catarrhalis.
b % of isolates susceptible according to NCCLS breakpoints.
c NCCLS (SAST 2003) approved breakpoint for H. influenzae: susceptible 4 mg/L; NA = NCCLS breakpoints not available.2 mg/L) phenotypes amongst isolates of S. pneu-
moniae.2,9,14 During the 1999—2000 winter season,
44.5% of S. pneumoniae RTI isolates from Japan
were penicillin resistant and 19.8% were penicillin
intermediate, a pattern with small geographic var-
iation throughout Japan (Table 1). In previous stu-
dies, Yoshida et al.15 found that penicillin resistance
increased from 4.3% in 1988 to 9.8% in 1992 and
Sahm et al.10 reported 10.1% penicillin resistance
for the 1997—98 winter season. Therefore, penicillin
resistance in Japan is increasing and current data
strongly suggest that the trend has accelerated in
recent years.
Resistance to penicillin in S. pneumoniae is
mediated by changes in the affinity of high mole-
cular weight penicillin binding proteins (PBPs) for
their substrates. As these PBPs are also targets for
other b-lactams, the activity of aminopenicillins,
cephalosporins and carbapenems is also reduced
against penicillin-resistant strains. This is most evi-
dent with compounds considered active only against
penicillin-susceptible S. pneumoniae, such as cefa-clor and cefixime. Cefuroxime, cefpodoxime and
cefdinir retained some activity against penicillin-
intermediate isolates (approximately 40%), but lit-
tle or no activity against resistant isolates. This
perhaps reflects the trend towards greater resis-
tance as previous work has shown that cefuroxime,
among other cephalosporins, can retain activity
against many penicillin-resistant strains.16,17 The
most effective b-lactams for the 1999—2000 winter
season in Japan were cefditoren and amoxicillin—
clavulanate, with over 90% susceptibility among
penicillin-resistant strains. The amoxicillin—clavu-
lanate results can be extrapolated to include amox-
icillin as an effective b-lactam (92% susceptibility
among penicillin-resistant strains), although amox-
icillin itself was not tested against S. pneumoniae.
Macrolides form the principal alternative to b-
lactams for the treatment of lower RTIs involving S.
pneumoniae. However, it is now clear that this class
of compounds, including erythromycin, clarithromy-
cin and azithromycin, is seriously compromised by
the development of resistance not only as a result of
34 M. Inoue et al.the increasing prevalence of penicillin-resistant
pneumococci but also, in Japan, among penicillin-
susceptible strains.
Typical of the Far East, S. pneumoniae macrolide
resistance in Japan is high (77.9%) with some centre
variation (67.3—86.4%). This finding of 77.9% is
considerably higher than the 66.5% reported for
the 1997—1998 winter season.10 The proportion of
penicillin-resistant isolates (n = 137) that are also
macrolide-resistant has not increased over the same
period (124/137, 90.5%) and is slightly lower than
the previous study (1997—1998, 95.5%).
Two main mechanisms are known to account for
macrolide resistance in S. pneumoniae. With the
first, resistance is associated with specific mutation
within the erm gene that confers resistance to most
macrolides, lincosamides and streptogramin B anti-
biotics.18 With the second, the so-called M pheno-
type, resistance is mediated by an efflux mechanism
due to the presence of themef(A) gene that confers
resistance to 14- and 15-membered macrolides.19
Growing macrolide resistance is of increasing con-
cern, especially that dependent upon the erm(B)
genotype; not only because it is the more potent
macrolide resistance, but because resistance to
other antimicrobial compounds appear preferen-
tially to be associated with it. This study shows that
in Japan, the distribution of erm(B) and mef(A) are
similar.
Telithromycin, a synthetic ketolide derived by
chemical modification of desclarithromycin, was
designed to maintain potent antimicrobial activity
against community-acquired respiratory tract infec-
tion (CARTI) pathogens, even macrolide-resistant
pneumococci, and not to induce resistance due to
erm(B).20 There was, however, an upward shift in
telithromycin MICs among the isolates with erm(B)-
mediated macrolide resistance compared with
mef(A) strains. This effect of erm(B) resistance on
the activity of telithromycin has been reported
previously although, as in this study, all the isolates
were still found to be inhibited by telithromycin at
1 mg/L.
Worldwide incidence of fluoroquinolone-resistant
S. pneumoniae (levofloxacin MIC 8 mg/L) is rare,
although it tends to be concentrated in pockets of
Asia (specifically Hong Kong) and North America.
The four (1.3%) resistant isolates from Japan were
obtained from four different centres, and would
therefore suggest random distribution and indepen-
dent origin.
Streptococcus pyogenes
Streptococcus pyogenes was susceptible to most
of the antimicrobials tested with the notableexception of the macrolides (17.5% resistant, mostly
mef(A)). Telithromycin was 16- to 32-fold more
potent than the macrolides although penicillin
remains the most potent antimicrobial.
Haemophilus influenzae
There is considerable variability worldwide in the
prevalence of b-lactamase production by H. influ-
enzae, with previous studies showing values of 19%
for Europe, 42% for the USA and around 14% for
Japan.10,21,22 The value for Japan is slightly higher
than the finding here of 8.5%. Only a single (0.36%)
b-lactamase-negative ampicillin-resistant (BLNAR)
(ampicillin MIC 4 mg/L) strain was isolated in
Japan during the winter season 1999—2000,
although 3.2% of isolates were b-lactamase-nega-
tive with low-level resistance to ampicillin (MIC
2 mg/L). These values are considerably lower that
those published for Japan by Hasegawa et al.23
Of the b-lactams tested, cefixime (100%), cefpo-
doxime (99.3%), cefuroxime (95.4%), and cefdinir
(91.8%) were the most active, followed by ampicillin
(87.9%), cefaclor (86.5%), and amoxicillin (81.5%),
(Table 4). b-lactamase production conferred resis-
tance to ampicillin and amoxicillin for all isolates, but
had little or no effect on susceptibility to cefixime,
cefpodoxime, and cefuroxime. For cefdinir and cefa-
clor the effect was partial, susceptibility being
reduced by approximately 15% and 50%, respectively.
Similar partial co-resistance was observed for
chloramphenicol and tetracycline, where 99.6%
and 97.7% b-lactamase-negative isolates were sus-
ceptible compared with 62.5% and 50% b-lactamase-
positive isolates, respectively.
All isolates were susceptible to azithromycin,
with 88.3% susceptible to clarithromycin. For the
1997—1998 winter season, Sahm et al. also found
100% susceptibility of isolates to azithromycin,10
with 93.2% susceptible to clarithromycin, indicating
a slightly increased resistance towards this macro-
lide. In 1999—2000, the azithromycin MICs for the
Japanese isolates were all 2 mg/L. All isolates of
H. influenzae were susceptible to the ketolide teli-
thromycin at 4 mg/L.
Moraxella catarrhalis
b-lactamase production was observed in 96.7% ofM.
catarrhalis isolates tested in Japan, a figure almost
identical to 97.5% reported by Sahm et al.10 for the
1997—98 winter season. b-lactamase-producing
strains of M. catarrhalis were first reported in the
late 1970s and by the late 1980s, these strains were
predominant, accounting for more than 80% of clin-
ical isolates in a number of studies.8,24,25
Antimicrobial susceptibility of respiratory tract pathogens 35The b-lactamases of M. catarrhalis are inhibited
by clavulanic acid and the combination of amoxi-
cillin—clavulanic acid has been shown to be highly
active against this species.25—29 Indeed, in this
study, among b-lactamase-positive M. catarrhalis
the MIC90 for unprotected ampicillin was high at
16 mg/L, in contrast with 0.25 mg/L for amoxicil-
lin—clavulanate.Summary
Despite growing public awareness Japan has wit-
nessed increased and even accelerating resistance
to the macrolides and to b-lactams. Fluoroquino-
lone resistance, albeit at a low level, would also
appear to be endemic. This study documents
the high prevalence of antimicrobial resistance
and co-resistance among respiratory pathogens in
Japan.
For a great proportion of respiratory infections
that require antimicrobial therapy, amoxicillin
remains largely effective; however, in Japan, the
preference is for the use of newer drugs as first-
line treatment. This study reinforces the necessity
for judicious use of old and new antimicrobial com-
pounds and, with the technical ability that is now
available, to evaluate resistance at a genetic level
to monitor more detailed patterns of emergence.Acknowledgments
The PROTEKTsurveillance survey is funded by in part
Aventis. We gratefully acknowledge the contribu-
tion of the scientific staff of GR Micro Ltd, London,
UK. Data analysis was undertaken by Micron
Research Ltd, Upwell, Cambridgeshire, UK.
Conflict of interest: No conflict of interest
declared.References
1. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to
support the rationale that bacterial eradication in respiratory
tract infection is an important aim of antimicrobial therapy. J
Antimicrob Chemother 2001;47:129—40.
2. Felmingham D, Gru¨neberg RN. The Alexander Project 1996—
1997: latest susceptibility data from this international study
of bacterial pathogens from community-acquired lower
respiratory tract infections. J Antimicrob Chemother
2000;45:191—203.
3. Baquero F. Pneumococcal resistance to b-lactam antibiotics:
A global geographic overview. Microb Drug Resist 1995;1:
115—20.4. Song JH, Lee NY, Ichiyama S. The Asian Network for Surveil-
lance of Resistant Pathogens (ANSORP) Study Group. Spread
of drug-resistant Streptococcus pneumoniae in Asian coun-
tries: Asian Network for Surveillance of Resistant Pathogens
(ANSORP) study. Clin Infect Dis 1999;28:1206—11.
5. Karlowsky JA, Thornsberry C, Critchley IA, et al. Suscept-
ibilities to levofloxacin in Streptococcus pneumoniae, Hae-
mophilus influenzae, and Moraxella catarrhalis clinical
isolates from children: results from 2000—2001 and 2001—
2002 TRUST studies in the United States. Antimicrob Agents
Chemother 2003;47:1790—7.
6. Hu YY, Yu SJ, Liu G, Gao W, Yang YH. Antimicrobial suscept-
ibility of Haemophilus influenzae among children in Beijing,
China, 1999—2000. Acta Paediatr 2002;91:136—40.
7. Gru¨neberg RN, Felmingham D. Results of the Alexander
Project: a continuing, multicenter study of the antimicrobial
susceptibility of community-acquired, lower respiratory
tract bacterial pathogens. Diagn Microbiol Infect Dis
1996;25:169—81.
8. Mandell LA. Community-acquired pneumonia: Etiology, epi-
demiology and treatment. Chest 1995;108:35S—42S.
9. Ball P. Epidemiology and treatment of chronic bronchitis and
its exacerbations. Chest 1995;108:43S—52S.
10. Goldstein F, Bryskier A, Appelbaum PC, et al. The etiology of
respiratory tract infections and the antibacterial activity of
fluoroquinolones and other oral bacterial agents against
respiratory pathogens. Clin Microbiol Infect 1998;4:2S8—18.
11. Felmingham D. Antibiotic resistance: Do we need new ther-
apeutic approaches? Chest 1995;108:70S—8S.
12. Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thorns-
berry C. Resistance surveillance of Streptococcus pneumo-
niae, Haemophilus influenzae and Moraxella catarrhalis
isolated in Asia and Europe, 1997—1998. J Antimicrob Che-
mother 2000;45:457—66.
13. Felmingham D. The need for antimicrobial resistance sur-
veillance. J Antimicrob Chemother 2002;50:1—7.
14. National Committee for Clinical Laboratory Standards. Per-
formance standards for antimicrobial susceptibility testing —
twelfth informational supplement M100—S12. NCCLS,
Wayne, PA, USA, 2002.
15. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Detection of
macrolide resistance mechanisms in Streptococcus pneumo-
niae and Streptococcus pyogenes using a multiplex rapid-
cycle PCR with microwell-format probe hybridization. J Anti-
microb Chemother 2001;48:541—4.
16. Jones RN. The emergent needs for basic research, education
and surveillance of antimicrobial resistance. Problems facing
the report from the American Society for Microbiology Task
Force on Antimicrobial Resistance. Diagn Microbiol Infect Dis
1996;25:153—61.
17. Yoshida R, Kaku M, Kohno S, et al. Trends in antimicrobial
resistance of Streptococcus pneumoniae in Japan. Antimi-
crob Agents Chemother 1995;39:1196—8.
18. Klugman KP. Pneumococcal resistance to antibiotics. Clin
Microb Rev 1990;3:171—96.
19. Linares J, Alonso T, Perez JL, et al. Decreased susceptibility
of penicillin-resistant pneumococci to twenty-four b-lactam
antibiotics. J Antimicrob Chemother 1992;30:279—88.
20. Trieu-Cuot P, Poyart-Salmeron C, Carlier C, Courvalin P.
Nucleotide sequence of the erythromycin resistance gene
of the conjugative transposon Tn1545. Nuc Acids Res
1990;18:3660—6.
21. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneu-
moniae and Streptococcus pyogenes resistant to macrolides
but sensitive to clindamycin: a common resistance pattern
mediated by an efflux system. Antimicrob Agents Chemother
1998;40:1817—24.
36 M. Inoue et al.22. Bryskier A. Novelties in the field of anti-infectives in 1997.
Clin Infect Dis 1998;2:865—83.
23. Morosini M-II., Canton R, Loza E, et al. In vitro activity of
telithromycin against Spanish Streptococcus pneumoniae iso-
lates with characterized macrolide resistance mechanisms.
Antimicrob Agents Chemother 2001;45:2427—31.
24. Ohkusu K, Nakamura A, Sawada K. Antibiotic resistance
among recent clinical isolates of Haemophilus influenzae
in Japanese children. Diagn Microbiol Infect 2000;36:249—
54.
25. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA,
Appelbaum PC. Susceptibilities of Streptococcus pneumoniae
and Haemophilus influenzae to 10 oral antimicrobial
agents based on pharmacodynamic parameters: 1997 US
surveillance study. Antimicrob Agents Chemother 1999;43:
1901—8.26. Hasegawa K, Yamamoto K, Chiba N, et al. Diversity of ampi-
cillin-resistance genes in Haemophilus influenzae in Japan
and the United States. Microb Drug Resist 2003;9:39—46.
27. Catlin BW. Branhamella catarrhalis: an organism gaining
respect as a pathogen. Clin Microbiol Rev 1990;3:293—320.
28. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS.
Antimicrobial resistance among respiratory isolates of Hae-
mophilus influenzae, Moraxella catarrhalis, and Streptococ-
cus pneumoniae in the United States. Antimicrob Agents
Chemother 1990;34:2075—80.
29. Doern GV, Bruggemann AB, Pierce G, Hogan T, Holley HP,
Rauch A. Prevalence of antimicrobial resistance among 723
outpatient clinical isolates of Moraxella catarrhalis in the
United States in 1994 and 1995: results of a 30-center
national surveillance study. Antimicrob Agents Chemother
1996;40:2884—6.
